173 related articles for article (PubMed ID: 38323423)
1. Real-world data on siponimod-related lymphopenia among people with secondary progressive multiple sclerosis.
Gilmartin CG; Hoyle N; Garjani A; Dixon T; Jos H; Paling D; Brownlee W; Tench C; Evangelou N
Mult Scler; 2024 Apr; 30(4-5):600-604. PubMed ID: 38323423
[TBL] [Abstract][Full Text] [Related]
2. Humoral immune response to COVID-19 vaccines in people with secondary progressive multiple sclerosis treated with siponimod.
Krbot Skorić M; Rogić D; Lapić I; Šegulja D; Habek M
Mult Scler Relat Disord; 2022 Jan; 57():103435. PubMed ID: 34920248
[TBL] [Abstract][Full Text] [Related]
3. Siponimod for multiple sclerosis.
Cao L; Li M; Yao L; Yan P; Wang X; Yang Z; Lao Y; Li H; Yang K; Li K
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD013647. PubMed ID: 34783010
[TBL] [Abstract][Full Text] [Related]
4. Short- and long-term effects of siponimod on autonomic nervous system in secondary progressive multiple sclerosis.
Habek M; Junaković A; Karić A; Crnošija L; Barun B; Gabelić T; Adamec I; Krbot Skorić M
Mult Scler Relat Disord; 2022 Aug; 64():103966. PubMed ID: 35724530
[TBL] [Abstract][Full Text] [Related]
5. Peripheral oedema as an adverse effect of treatment of secondary progressive multiple sclerosis with siponimod: A case series.
Chang EH; Hardy TA
J Neuroimmunol; 2024 Apr; 389():578330. PubMed ID: 38493554
[TBL] [Abstract][Full Text] [Related]
6. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.
Kappos L; Bar-Or A; Cree BAC; Fox RJ; Giovannoni G; Gold R; Vermersch P; Arnold DL; Arnould S; Scherz T; Wolf C; Wallström E; Dahlke F;
Lancet; 2018 Mar; 391(10127):1263-1273. PubMed ID: 29576505
[TBL] [Abstract][Full Text] [Related]
7. [The efficacy and safety of siponimod in the Russian population of patients with secondary progressive multiple sclerosis].
Evdoshenko EP; Neofidov NA; Bakhtiyarova KZ; Davydovskaya MV; Kairbekova EI; Kolontareva YM; Malkova NA; Odinak MM; Popova EV; Sazonov DV; Stolyarov ID; Smagina IV; Fedyanin AS; Habirov FA; Khaibullin TI; Khachanova NV; Shchukin IA; Boyko AN
Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(10. Vyp. 2):110-119. PubMed ID: 31934996
[TBL] [Abstract][Full Text] [Related]
8. [Siponimod: a new view at the therapy of secondary progressive multiple sclerosis].
Krasnov VS; Kolontareva YM
Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(7):124-129. PubMed ID: 34460168
[TBL] [Abstract][Full Text] [Related]
9. [The first russian experience of use of siponimod in real clinical practice].
Prakhova LN; Ilves AG
Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(7):138-141. PubMed ID: 35904305
[TBL] [Abstract][Full Text] [Related]
10. Stick or twist? Cost-effectiveness of siponimod compared with continuing existing disease-modifying therapies in the treatment of active secondary progressive multiple sclerosis in the UK.
Montgomery S; Woodhouse F; Vudumula U; Gudala K; Duddy M; Kroes M
J Med Econ; 2022; 25(1):669-678. PubMed ID: 35575251
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years.
Cree BA; Arnold DL; Fox RJ; Gold R; Vermersch P; Benedict RH; Bar-Or A; Piani-Meier D; Rouyrre N; Ritter S; Kilaru A; Karlsson G; Giovannoni G; Kappos L
Mult Scler; 2022 Sep; 28(10):1591-1605. PubMed ID: 35380078
[TBL] [Abstract][Full Text] [Related]
12. Autonomic nervous system abnormalities predict cardiovascular changes after initiation of siponimod in secondary progressive multiple sclerosis.
Habek M; Crnošija L; Junaković A; Adamec I; Barun B; Gabelić T; Krbot Skorić M
Clin Neurophysiol; 2021 Feb; 132(2):581-585. PubMed ID: 33461086
[TBL] [Abstract][Full Text] [Related]
13. Matching-adjusted indirect treatment comparison of siponimod and other disease modifying treatments in secondary progressive multiple sclerosis.
Samjoo IA; Worthington E; Haltner A; Cameron C; Nicholas R; Rouyrre N; Dahlke F; Adlard N
Curr Med Res Opin; 2020 Jul; 36(7):1157-1166. PubMed ID: 32220214
[No Abstract] [Full Text] [Related]
14. Siponimod and Cognition in Secondary Progressive Multiple Sclerosis: EXPAND Secondary Analyses.
Benedict RHB; Tomic D; Cree BA; Fox R; Giovannoni G; Bar-Or A; Gold R; Vermersch P; Pohlmann H; Wright I; Karlsson G; Dahlke F; Wolf C; Kappos L
Neurology; 2021 Jan; 96(3):e376-e386. PubMed ID: 33328324
[TBL] [Abstract][Full Text] [Related]
15. Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study.
Gold R; Piani-Meier D; Kappos L; Bar-Or A; Vermersch P; Giovannoni G; Fox RJ; Arnold DL; Benedict RHB; Penner IK; Rouyrre N; Kilaru A; Karlsson G; Ritter S; Dahlke F; Hach T; Cree BAC
J Neurol; 2022 Sep; 269(9):5093-5104. PubMed ID: 35639197
[TBL] [Abstract][Full Text] [Related]
16. Siponimod for Cognition in Secondary Progressive Multiple Sclerosis: Thinking Through the Evidence.
Leavitt VM; Rocca M
Neurology; 2021 Jan; 96(3):91-92. PubMed ID: 33328322
[No Abstract] [Full Text] [Related]
17. Cost Effectiveness and Budget Impact of Siponimod Compared to Interferon Beta-1a in the Treatment of Adult Patients with Secondary Progressive Multiple Sclerosis with Active Disease in Switzerland.
Schur N; Gudala K; Vudumula U; Vadapalle S; Bhadhuri A; Casanova A; Adlard N; Schwenkglenks M
Pharmacoeconomics; 2021 May; 39(5):563-577. PubMed ID: 33791945
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness and budget impact analysis of siponimod in the treatment of secondary progressive multiple sclerosis in Italy.
Cortesi PA; Antonazzo IC; Gasperini C; Nica M; Ritrovato D; Mantovani LG
PLoS One; 2022; 17(3):e0264123. PubMed ID: 35259168
[TBL] [Abstract][Full Text] [Related]
19. The importance of considering differences in study and patient characteristics before undertaking indirect treatment comparisons: a case study of siponimod for secondary progressive multiple sclerosis.
Samjoo IA; Worthington E; Haltner A; Cameron C; Nicholas R; Dahlke F; Adlard N
Curr Med Res Opin; 2020 Jul; 36(7):1145-1156. PubMed ID: 32216597
[No Abstract] [Full Text] [Related]
20. Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis.
Cree BA; Magnusson B; Rouyrre N; Fox RJ; Giovannoni G; Vermersch P; Bar-Or A; Gold R; Piani Meier D; Karlsson G; Tomic D; Wolf C; Dahlke F; Kappos L
Mult Scler; 2021 Sep; 27(10):1564-1576. PubMed ID: 33205682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
